Merck Buys Idenix for $3.9B in Yet Another Blockbuster Hep C Deal

NEW YORK (TheStreet) -- Most investors probably believed hepatitis C deal making was done, but not so, as Merck (MRK) surprised many folks Monday morning by announcing plans to acquire Idenix Pharmaceuticals (IDIX) for $3.85 billion. 

The all-cash deal values Idenix at $24.50 per share, or more than three times the stock's Friday close of $7.23 per share. 

With Gilead Sciences (GILD) already marketing the hepatitis C pill Sovaldi and competition from Abbvie (ABBV)-Enanta Pharma (ENTA) and Bristol-Myers Squibb  (BMY) close behind, a lot of investors believed the hepatitis C drug race had transitioned to marketing and away from M&A. But Merck chief scientitist Roger Perlmutter is no dummy, so his decision to spend almost $4 billion on Idenix says the hepatitis C treatment market may have a much longer tail than many believed. 

In an interview with Forbes, Perlmutter said the future of hepatitis C therapy is triple-drug combinations that may reduce the duration of treatment from two months with Gilead's treatments to as little as one month. "Let's recognize that there are on the order of 170 million people who have hepatitis C infection," Perlmutter told Forbes. "You're not going to treat a substantial fraction of the world's infections in a few years. It's just impossible."

Merck's existing hepatitis C drug pipeline includes MK-5172 and MK-8472. Acquiring Idenix adds three more hepatitis C drugs, including IDX2147, IX21459 and samatasavir. Merck's stated goal is to develop a single-pill, once-daily therapy against all subtypes of hepatitis C. 

The $3.85 billion acquisition is an amazing comeback story for Idenix, which has faced considerable setbacks in recent years dealing with delays and FDA-ordered clinical holds on some of its older hepatitis C drugs. But throughout the disappointments, Idenix CEO Ron Renaud has been steadfast in his belief that Idenix still had a role to play in hepatitis C drug development. "I know there's a perception that we're late to [hepatitis C] but the market will take a long time to play out and there will be plenty of room to operate when we get there," said Renaud last January, after raising more than $100 million from Boston-based hedge fund, The Baupost Group.

On Monday, Renaud, his employees and shareholders couldn't agree more. 

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Investing

When Is It 'Worth It' to Work With a Financial Advisor?

When Is It 'Worth It' to Work With a Financial Advisor?

Amazon, Microsoft and Google Face Backlash over ICE, Military Deals

Amazon, Microsoft and Google Face Backlash over ICE, Military Deals

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In

Why Millennials Are Ditching Stocks for ETFs

Why Millennials Are Ditching Stocks for ETFs

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says